Processa Pharmaceuticals
Business Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
601 21st St Ste 300, Vero Beach, Florida...Phone Number
(772) 453-2899Revenue
-Stock Symbol
PCSAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
2
1
About Processa Pharmaceuticals
Processa Pharmaceuticals is a development-stage company dedicated to improving the quality of life for individuals suffering from life-threatening and life-compromising chronic diseases. The company pursues a unique approach, focusing on the development, rather than the initial discovery, of pharmacological solutions, particularly in oncology and other areas with significant unmet medical needs. Their mission is to create effective treatments for patients who currently have limited or poor options. The leadership team leverages extensive experience in regulatory science and clinical development, employing a patient-centric and de-risked strategy intended to efficiently bring new therapies to market.Explore more
Processa Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Processa Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Processa Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Processa Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Processa Pharmaceuticals has new funding data
Earning: See what the market has to say on Processa Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Processa Pharmaceuticals
Processa Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Processa Pharmaceuticals had a recent Job posting/layoffs
Check if Processa Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Processa Pharmaceuticals
Find more new buyers
Compare Similar Companies to Processa Pharmaceuticals
Compare insights from companies similar to Processa Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Processa Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Processa Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Processa Pharmaceuticals.
Processa Pharmaceuticals financials insights
Gather financial insights about Processa Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Debt
$2.6M
2020
Debt
$150K
2021
Share Placement
$10.2M
2026
Stock/Share Issuance
$200M
Processa Pharmaceuticals Tech Stack
A closer look at the technologies used by Processa Pharmaceuticals
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Person-Based
Person-Based
Person-Based
Funding
Funding
Processa Pharmaceuticals News & Media
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
VERO BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Processa) (Nasdaq: PCSA) today announced it has acquired Vidya Therapeutics, Inc. (Vidya), a clinical-stage biotechnology company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases with an initial focus on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis.Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive Officer, and Patrick Lin, Chief Business & Strategy Officer and Founder, will attend the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California.Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Interim safety and efficacy data to be reported in Q1
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Processa Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Processa Pharmaceuticals is a development-stage company dedicated to improving the quality of life for individuals suffering from life-threatening and life-compromising chronic diseases. The company pursues a unique approach, focusing on the development, rather than the initial discovery, of pharmacological solutions, particularly in oncology and o... Read More
